# Safety and Effectiveness of the PXL-Platinum 330 System for CXL Using Riboflavin Solution

> **NCT04177082** · PHASE1 · COMPLETED · sponsor: **Cornea Associates of Texas** · enrollment: 200 (actual)

## Conditions studied

- Keratoconus
- Pellucid Marginal Corneal Degeneration
- Corneal Degeneration
- Corneal Ectasia

## Interventions

- **COMBINATION_PRODUCT:** PXL-330 Platinum device for crosslinking with Peschke riboflavin solution

## Key facts

- **NCT ID:** NCT04177082
- **Lead sponsor:** Cornea Associates of Texas
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-10
- **Primary completion:** 2022-05-05
- **Final completion:** 2022-05-05
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2022-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04177082

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04177082, "Safety and Effectiveness of the PXL-Platinum 330 System for CXL Using Riboflavin Solution". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04177082. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*